Literature DB >> 85016

Is chloroquine obsolete in treatment of rheumatic disease?

J S Marks, B J Power.   

Abstract

Retinal changes associated with chloroquine occurred in 22 out of 222 patients on long-term therapy for rheumatic diseases and were related to patient age, total dose, and duration of treatment. Ophthalmic review showed progression of the retinopathy with deterioration of visual acuity in only 1 case while the remainder retained normal vision. The results suggest that the risks of ocular toxicity related to chloroquine therapy are acceptably low.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 85016     DOI: 10.1016/s0140-6736(79)92905-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  7 in total

1.  Treatment of palindromic rheumatism with chloroquine.

Authors:  M R Richardson; A M Zalin
Journal:  Br Med J (Clin Res Ed)       Date:  1987-03-21

2.  Toxicity and side-effects of antimalarials in Africa: a critical review.

Authors:  L A Salako
Journal:  Bull World Health Organ       Date:  1984       Impact factor: 9.408

Review 3.  Adverse ocular reactions to drugs.

Authors:  M A Spiteri; D G James
Journal:  Postgrad Med J       Date:  1983-06       Impact factor: 2.401

4.  Chloroquine in long-term treatment of rheumatoid arthritis.

Authors:  A Bjelle; A Björnham; A Larsen; T Mjörndal
Journal:  Clin Rheumatol       Date:  1983-12       Impact factor: 2.980

5.  Chloroquine retinopathy: is there a safe daily dose?

Authors:  J S Marks
Journal:  Ann Rheum Dis       Date:  1982-02       Impact factor: 19.103

6.  Biochemical indices of response to hydroxychloroquine and sodium aurothiomalate in rheumatoid arthritis.

Authors:  J S Dixon; M E Pickup; H A Bird; M R Lee; V Wright; W W Downie
Journal:  Ann Rheum Dis       Date:  1981-10       Impact factor: 19.103

Review 7.  Rheumatoid arthritis in the aged. Incidence and optimal management.

Authors:  G Nesher; T L Moore
Journal:  Drugs Aging       Date:  1993 Nov-Dec       Impact factor: 3.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.